Cargando…

Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

Detalles Bibliográficos
Autores principales:	Yasumizu, Yota, Rajabi, Hasan, Jin, Caining, Hata, Tsuyoshi, Pitroda, Sean, Long, Mark D., Hagiwara, Masayuki, Li, Wei, Hu, Qiang, Liu, Song, Yamashita, Nami, Fushimi, Atsushi, Kui, Ling, Samur, Mehmet, Yamamoto, Masaaki, Zhang, Yan, Zhang, Ning, Hong, Deli, Maeda, Takahiro, Kosaka, Takeo, Wong, Kwok K., Oya, Mototsugu, Kufe, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039914/ https://www.ncbi.nlm.nih.gov/pubmed/32094369 http://dx.doi.org/10.1038/s41467-020-14808-w

Ejemplares similares

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2020)

MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells
por: Hagiwara, Masayuki, et al.
Publicado: (2021)

Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
por: Fushimi, Atsushi, et al.
Publicado: (2022)

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas
por: Luan, Zhou, et al.
Publicado: (2021)

Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells
por: Rajabi, Hasan, et al.
Publicado: (2019)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

MUC1-C REPRESSES THE RASSF1A TUMOR SUPPRESSOR IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2019)

Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells
por: Jin, Caining, et al.
Publicado: (2012)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Yamashita, Nami, et al.
Publicado: (2021)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2022)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer
por: Yamashita, Nami, et al.
Publicado: (2022)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
por: Alam, Maroof, et al.
Publicado: (2014)

MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER
por: Takahashi, Hidekazu, et al.
Publicado: (2015)

MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER
por: Bouillez, Audrey, et al.
Publicado: (2017)

TARGETING THE eIF4A RNA HELICASE BLOCKS TRANSLATION OF THE MUC1-C ONCOPROTEIN
por: Jin, Caining, et al.
Publicado: (2012)

Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment
por: Morimoto, Yoshihiro, et al.
Publicado: (2022)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

MUC1-C activates EZH2 expression and function in human cancer cells
por: Rajabi, Hasan, et al.
Publicado: (2017)

Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer
por: Kufe, Donald
Publicado: (2023)

DNA METHYLATION BY DNMT1 AND DNMT3b METHYLTRANSFERASES IS DRIVEN BY THE MUC1-C ONCOPROTEIN IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2016)

COOPERATIVITY OF THE MUC1 ONCOPROTEIN AND STAT1 PATHWAY IN POOR PROGNOSIS HUMAN BREAST CANCER
por: Khodarev, Nikolai, et al.
Publicado: (2009)

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells
por: Bhattacharya, Atrayee, et al.
Publicado: (2022)

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2021)

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2022)

Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy
por: Hakozaki, Kyohei, et al.
Publicado: (2022)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy
por: Matsumoto, Kazuhiro, et al.
Publicado: (2021)

Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
por: Mizuno, Ryuichi, et al.
Publicado: (2022)

MUC1-C drives DNA methylation in cancer
por: Rajabi, Hasan, et al.
Publicado: (2016)

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS
por: Raina, Deepak, et al.
Publicado: (2013)

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression
por: Yamashita, Nami, et al.
Publicado: (2022)

Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference
por: Fujita, Kazutoshi, et al.
Publicado: (2022)

Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer
por: Ide, Hiroki, et al.
Publicado: (2013)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
por: Yamashita, Nami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pod066j7efoqsfdbk2vmlargst